US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Blossomhill Therapeutics Inc

18.64

-2.7300-12.77%

Post-market: 18.640.00000.00%17:50 EDT

Volume:362.16K

Turnover:6.89M

Market Cap:592.47M

PE:-7.63

High:21.24

Open:21.24

Low:18.41

Close:21.37

52wk High:27.99

52wk Low:15.25

Shares:31.78M

Float Shares:9.38M

Volume Ratio:1.71

T/O Rate:3.86%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.4440

EPS(LYR):-24.8342

ROE:--

ROA:--

PB:-3.39

PE(LYR):-0.75

Loading ...

Overview Company News Filings

BlossomHill Therapeutics Advances Pan-KRAS Inhibitor BH-501284 Toward Q1 2027 IND Filing After Preclinical Data Presentation

BlossomHill Therapeutics price target raised to $40 from $36 at Leerink

Blossomhill Therapeutics Inc : JP Morgan Raises Target Price to $30 from $28

THOMSON REUTERS

BlossomHill Therapeutics Price Target Raised to $40.00/Share from $30.00 by Guggenheim

US Research Roundup-eBay, Sunbelt Rentals, T-Mobile

Blossomhill Therapeutics Inc : Guggenheim Raises Target Price to $40 from $30

THOMSON REUTERS

BlossomHill Therapeutics Q2 Loss Widens

MT Newswires Live

Earnings Flash (BLSM) BlossomHill Therapeutics Posts Q2 Loss $8.75 a Share

MT Newswires Live

BlossomHill Therapeutics Q2 EPS $(8.75)

Benzinga Earnings

BlossomHill Net Loss Widens 79.35% to $23.8 Million in Q2 FY26; R&D Expenses Rise 70.78% to $21.4 Million

Blossomhill Therapeutics Reports Second Quarter 2026 Financial Results

THOMSON REUTERS

Blossomhill Therapeutics - Q2 2026 Net Loss $23.80 Mln, $-8.75 Per Share

THOMSON REUTERS

Press Release: BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results

BlossomHill: Buy Rating Reiterated as BH-30643 Data Strengthen Case for C797S-Focused Path; $32 Price Target Maintained

BlossomHill updates BH-30643 lung cancer trial results

BlossomHill Drug Shows 45% Response Rate in Lung Cancer Trial

MT Newswires Live

BlossomHill Therapeutics announces updated SOLARA trial data

Blossomhill Therapeutics - to Initiate Global Phase 2 Study for Egfr C797s-Positive Nsclc in Q1 2027

THOMSON REUTERS

BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer

Leerink Partners Initiates BlossomHill Therapeutics at Outperform, $36 Price Target

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/BLSM/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BLSM","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BLSM\",,,,,undefined,":{"symbol":"BLSM","market":"US","secType":"STK","nameCN":"Blossomhill Therapeutics Inc","latestPrice":18.64,"timestamp":1790798400000,"preClose":21.37,"halted":0,"volume":362159,"hourTrading":{"tag":"盘后","latestPrice":18.64,"preClose":18.64,"latestTime":"17:50 EDT","volume":3072,"amount":57262.08,"timestamp":1790805017139,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.127749181094993,"floatShares":9375000,"shares":31784899,"eps":-2.444,"marketStatus":"Post-Mkt","change":-2.73,"latestTime":"09-30 19:10:53 EDT","open":21.24,"high":21.24,"low":18.41,"amount":6891446.833292,"amplitude":0.132429,"askPrice":19.19,"askSize":1,"bidPrice":18.27,"bidSize":1,"shortable":0,"etf":0,"ttmEps":-2.444,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1790812800000},"marketStatusCode":4,"adr":0,"listingDate":1786075200000,"exchange":"NASDAQ","adjPreClose":21.37,"preHourTrading":{"tag":"盘前","latestPrice":21.37,"preClose":21.37,"latestTime":"09:29 EDT","volume":50,"amount":1068.5,"timestamp":1790774970072,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":18.64,"preClose":18.64,"latestTime":"17:50 EDT","volume":3072,"amount":57262.08,"timestamp":1790805017139,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.706412},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BLSM\",,,,,undefined,":{"symbol":"BLSM","floatShares":9375000,"roa":"--","roe":"--","lyrEps":-24.834182,"volumeRatio":1.706412,"shares":31784899,"dividePrice":0,"high":21.24,"amplitude":0.132429,"preClose":21.37,"low":18.41,"week52Low":15.25,"pbRate":"-3.39","week52High":27.99,"institutionHeld":0,"latestPrice":18.64,"eps":-2.444,"divideRate":0,"volume":362159,"delay":0,"ttmEps":-2.444,"open":21.24,"prevYearClose":16,"prevWeekClose":19.75,"prevMonthClose":18.3,"prevQuarterClose":16,"fiveDayClose":22.34,"twentyDayClose":18.99,"sixtyDayClose":16},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BLSM\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BLSM\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BLSM\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4,"buy":0.6,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6,"analysts":5,"updateTime":1788926400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/BLSM\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"BLSM","date":"2026-09-29","current":-7.594108,"percent":0.459459,"low":-11.561693,"twenty":-9.483269,"median":-8.079945,"eighty":-6.972365,"high":-2.788792,"avg":-8.198826,"sd":1.588815,"marketCap":678289958},"quantilePoints":[{"date":"2026-08-07","current":-6.897356,"twenty":-6.075643,"median":-4.843074,"eighty":-3.610505,"marketCap":490298560},{"date":"2026-08-14","current":-7.048236,"twenty":-7.038752,"median":-6.897356,"eighty":-6.893907,"marketCap":501023841},{"date":"2026-08-21","current":-6.811139,"twenty":-7.038752,"median":-6.955553,"eighty":-6.893907,"marketCap":484169828},{"date":"2026-08-28","current":-8.535478,"twenty":-7.10945,"median":-6.974951,"eighty":-6.897356,"marketCap":606744468},{"date":"2026-09-04","current":-8.630317,"twenty":-8.140605,"median":-7.054702,"eighty":-6.899943,"marketCap":613486073},{"date":"2026-09-11","current":-9.272633,"twenty":-8.535478,"median":-7.091344,"eighty":-6.910289,"marketCap":659145126},{"date":"2026-09-18","current":-11.561693,"twenty":-9.371783,"median":-7.940581,"eighty":-6.940465,"marketCap":821862961},{"date":"2026-09-25","current":-7.973591,"twenty":-9.483865,"median":-8.079945,"eighty":-6.970641,"marketCap":650637087},{"date":"2026-09-29","current":-8.312479,"twenty":-9.483269,"median":-8.079945,"eighty":-6.972365,"marketCap":678289958}],"updateTime":1790796257535},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BLSM\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2670239701","title":"BlossomHill Therapeutics Advances Pan-KRAS Inhibitor BH-501284 Toward Q1 2027 IND Filing After Preclinical Data Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2670239701","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670239701?lang=en_us&edition=fundamental","pubTime":"2026-09-28 19:01","pubTimestamp":1790593277,"startTime":"0","endTime":"0","summary":"BlossomHill Therapeutics advances pan-KRAS inhibitor BH-501284 toward Q1 2027 IND filing after preclinical data presentationBlossomHill Therapeutics presented preclinical data on BH-501284 at the AACR","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260928:nNDL5t9bQN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","SG9999014013.SGD","BK4585","IE00BQXX3D17.EUR","BK4588","IE00BN0W2T93.GBP","NDAQ","LU2210149790.SGD","BK4007","IE00BGHQF748.EUR","BCDF","LU0314104364.USD","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","SG9999014039.USD","IE00BKPKM429.USD","SG9999014005.SGD","LU2095319765.USD","LU2210150020.SGD","IE00BQXX3C00.GBP","IE00BN0W2V16.EUR","SG9999014021.USD","BLSM","IE00BQXX3F31.USD","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669162281","title":"BlossomHill Therapeutics price target raised to $40 from $36 at Leerink","url":"https://stock-news.laohu8.com/highlight/detail?id=2669162281","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669162281?lang=en_us&edition=fundamental","pubTime":"2026-09-22 00:20","pubTimestamp":1790007608,"startTime":"0","endTime":"0","summary":"Leerink raised the firm’s price target on BlossomHill Therapeutics (BLSM) to $40 from $36 and keeps an Outperform rating on the shares. Published f...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/blossomhill-therapeutics-price-target-raised-to-40-from-36-at-leerink-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/blossomhill-therapeutics-price-target-raised-to-40-from-36-at-leerink-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BLSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669904169","title":"Blossomhill Therapeutics Inc : JP Morgan Raises Target Price to $30 from $28","url":"https://stock-news.laohu8.com/highlight/detail?id=2669904169","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669904169?lang=en_us&edition=fundamental","pubTime":"2026-09-21 22:02","pubTimestamp":1789999370,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nFWN45D06Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BLSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669343166","title":"BlossomHill Therapeutics Price Target Raised to $40.00/Share from $30.00 by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2669343166","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669343166?lang=en_us&edition=fundamental","pubTime":"2026-09-21 21:07","pubTimestamp":1789996020,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BLSM/analyst-ratings","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669155576","title":"US Research Roundup-eBay, Sunbelt Rentals, T-Mobile","url":"https://stock-news.laohu8.com/highlight/detail?id=2669155576","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669155576?lang=en_us&edition=fundamental","pubTime":"2026-09-21 15:41","pubTimestamp":1789976490,"startTime":"0","endTime":"0","summary":"US RESEARCH ROUNDUP-eBay, Sunbelt Rentals, T-MobileSept 21 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several US-listed companies, including eBay, Sunbelt Ren","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nL4N45D0ES:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CL","SPAM","THNR","MTZ","TMUS","OKTA","AIRR","BUG","AMZA","EWTX","LU0109394709.USD","IBRN","LU2322448957.HKD","PKB","TTMX","GOSS","MLPA","PAGP","SUNB","LU1064131342.USD","THO","CDW","BLSM","ONLN","IHAK","IQMX","OKTG","EMLP","PSWD","AMLP","MCHB","EBAY","SRRK","BK4504","FOUR","AMRZ","HUBS","ARHS","OKTX","BK4528","HAKY","LU0251131958.USD","NBIX","BKH","CLIX","LU2095319765.USD","LU1201861249.SGD","PAA","STBQ","TTMI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669784131","title":"Blossomhill Therapeutics Inc : Guggenheim Raises Target Price to $40 from $30","url":"https://stock-news.laohu8.com/highlight/detail?id=2669784131","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669784131?lang=en_us&edition=fundamental","pubTime":"2026-09-21 11:20","pubTimestamp":1789960813,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nFWN45D00A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BLSM","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668492872","title":"BlossomHill Therapeutics Q2 Loss Widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2668492872","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668492872?lang=en_us&edition=fundamental","pubTime":"2026-09-18 19:42","pubTimestamp":1789731771,"startTime":"0","endTime":"0","summary":"BlossomHill Therapeutics  reported a Q2 loss on Friday of $8.75 per share, widening from a loss of $5.51 a year earlier.One analyst polled by FactSet expected a GAAP loss of $0.77.The company did not report any revenue for the quarter.Cash and cash equivalents for the quarter ended June 30 totaled $95.4 million, which, together with proceeds from its recent IPO, should be sufficient to fund operations into Q2 2028, the company said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BLSM","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668400179","title":"Earnings Flash (BLSM) BlossomHill Therapeutics Posts Q2 Loss $8.75 a Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2668400179","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668400179?lang=en_us&edition=fundamental","pubTime":"2026-09-18 19:12","pubTimestamp":1789729967,"startTime":"0","endTime":"0","summary":"Earnings Flash (BLSM) BlossomHill Therapeutics Posts Q2 Loss $8.75 a Share","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BLSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668798940","title":"BlossomHill Therapeutics Q2 EPS $(8.75)","url":"https://stock-news.laohu8.com/highlight/detail?id=2668798940","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668798940?lang=en_us&edition=fundamental","pubTime":"2026-09-18 19:08","pubTimestamp":1789729700,"startTime":"0","endTime":"0","summary":"BlossomHill Therapeutics (NASDAQ:BLSM) reported quarterly losses of $(8.75) per share. This is a 58.8 percent decrease over losses of $(5.51) per share from the same period last year.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/09/61864103/blossomhill-therapeutics-q2-eps-8-75","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668940172","title":"BlossomHill Net Loss Widens 79.35% to $23.8 Million in Q2 FY26; R&D Expenses Rise 70.78% to $21.4 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2668940172","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668940172?lang=en_us&edition=fundamental","pubTime":"2026-09-18 19:01","pubTimestamp":1789729260,"startTime":"0","endTime":"0","summary":"BlossomHill net loss widens 79.35% to $23.8 million in Q2 FY26; R&D expenses rise 70.78% to $21.4 millionBlossomHill posted a Q2 2026 net loss of $23.8 million, widening from $13.2 million a year earl","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260918:nNDL306CLY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","BK4112","LU2210149790.SGD","IE00BKPKM429.USD","IE00BQXX3D17.EUR","NDAQ","IE00BGHQF748.EUR","LU0314104364.USD","BLSM","BK4585","LU2210150020.SGD","SG9999014021.USD","IE00BQXX3F31.USD","IE00BN0W2T93.GBP","LU2095319765.USD","SG9999014013.SGD","SG9999014005.SGD","BK4007","IE00B64PRP62.GBP","IE00BQXX3C00.GBP","BK4588","SG9999014039.USD","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","BCDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668794092","title":"Blossomhill Therapeutics Reports Second Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2668794092","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668794092?lang=en_us&edition=fundamental","pubTime":"2026-09-18 19:00","pubTimestamp":1789729201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260918:nTUAXG6LB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BLSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668495940","title":"Blossomhill Therapeutics - Q2 2026 Net Loss $23.80 Mln, $-8.75 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2668495940","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668495940?lang=en_us&edition=fundamental","pubTime":"2026-09-18 19:00","pubTimestamp":1789729201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260918:nTUAXG6LB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BLSM","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668404309","title":"Press Release: BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2668404309","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668404309?lang=en_us&edition=fundamental","pubTime":"2026-09-18 19:00","pubTimestamp":1789729200,"startTime":"0","endTime":"0","summary":"proceeds from the initial public offering  in August 2026. -- Announced the U.S. Food and Drug Administration  granted Fast Track. designation to BH-30643, a macrocyclic OMNI-EGFR inhibitor, for the. treatment of adult patients with advanced or metastatic epidermal growth. after prior treatment with a third-generation EGFR tyrosine kinase. -- Presented preliminary results of BH-30643 from dose escalation and. backfill cohorts in the ongoing Phase 1/2 SOLARA trial in advanced or. metastatic EGFR-mutant NSCLC at the American Society of Clinical Oncology","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IPO","BK4588","TM","BK4007","03160","BK4585","BK4099","BLSM","BK4555","BK4604"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667462944","title":"BlossomHill: Buy Rating Reiterated as BH-30643 Data Strengthen Case for C797S-Focused Path; $32 Price Target Maintained","url":"https://stock-news.laohu8.com/highlight/detail?id=2667462944","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667462944?lang=en_us&edition=fundamental","pubTime":"2026-09-16 01:35","pubTimestamp":1789493756,"startTime":"0","endTime":"0","summary":"In a report released today, Charles Zhu from LifeSci Capital maintained a Buy rating on BlossomHill Therapeutics, Inc., with a price target of $32....","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/blossomhill-buy-rating-reiterated-as-bh-30643-data-strengthen-case-for-c797s-focused-path-32-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/blossomhill-buy-rating-reiterated-as-bh-30643-data-strengthen-case-for-c797s-focused-path-32-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BLSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667664478","title":"BlossomHill updates BH-30643 lung cancer trial results","url":"https://stock-news.laohu8.com/highlight/detail?id=2667664478","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667664478?lang=en_us&edition=fundamental","pubTime":"2026-09-15 19:57","pubTimestamp":1789473452,"startTime":"0","endTime":"0","summary":"BlossomHill Therapeutics, Inc. ( ($BLSM) ) has issued an announcement. On September 15, 2026, BlossomHill Therapeutics reported updated results fro...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/blossomhill-updates-bh-30643-lung-cancer-trial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/blossomhill-updates-bh-30643-lung-cancer-trial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BLSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667443426","title":"BlossomHill Drug Shows 45% Response Rate in Lung Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2667443426","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667443426?lang=en_us&edition=fundamental","pubTime":"2026-09-15 19:42","pubTimestamp":1789472523,"startTime":"0","endTime":"0","summary":"BlossomHill Therapeutics  said Tuesday that updated data from the phase 1/2 SOLARA trial of BH-30643 showed a 45% objective response rate and an 88% disease control rate in patients with EGFR C797S-positive non-small cell lung cancer following prior EGFR inhibitor treatment.Among 40 patients, 18 achieved a confirmed or ongoing unconfirmed partial response, while 25 remained on treatment at a median follow-up of 6.9 months, the company said.Among 174 patients treated at expansion doses of 40 mg, 50 mg or 60 mg twice daily, treatment-related dose reductions and discontinuations occurred in 9% and 3% of patients, respectively, BlossomHill said.BlossomHill plans to initiate a global phase 2 study targeting EGFR C797S-positive NSCLC in Q1 2027.Shares of the company were 6.7% higher in Tuesday premarket activity.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BLSM","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667864112","title":"BlossomHill Therapeutics announces updated SOLARA trial data","url":"https://stock-news.laohu8.com/highlight/detail?id=2667864112","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667864112?lang=en_us&edition=fundamental","pubTime":"2026-09-15 19:10","pubTimestamp":1789470625,"startTime":"0","endTime":"0","summary":"BlossomHill Therapeutics (BLSM) announced updated data from the ongoing Phase 1/2 SOLARA trial of BH-30643 in non-small cell lung cancerm or NSCLC,...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/blossomhill-therapeutics-announces-updated-solara-trial-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/blossomhill-therapeutics-announces-updated-solara-trial-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BLSM","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667641885","title":"Blossomhill Therapeutics - to Initiate Global Phase 2 Study for Egfr C797s-Positive Nsclc in Q1 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2667641885","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667641885?lang=en_us&edition=fundamental","pubTime":"2026-09-15 19:03","pubTimestamp":1789470205,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260915:nFWN4570C8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BLSM","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667141644","title":"BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2667141644","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667141644?lang=en_us&edition=fundamental","pubTime":"2026-09-15 19:00","pubTimestamp":1789470000,"startTime":"0","endTime":"0","summary":"45% objective response rate and 88% disease control rate observed in patients with EGFR C797S-positive resistance to prior EGFR inhibitors, with or without concurrent T790M, a difficult-to-treat popul","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/15/3361888/0/en/blossomhill-therapeutics-presents-updated-data-from-ongoing-phase-1-2-solara-trial-demonstrating-encouraging-anti-tumor-activity-of-omni-egfr-inhibitor-bh-30643-in-egfr-c797s-posit.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664285564","title":"Leerink Partners Initiates BlossomHill Therapeutics at Outperform, $36 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2664285564","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664285564?lang=en_us&edition=fundamental","pubTime":"2026-09-01 19:24","pubTimestamp":1788261848,"startTime":"0","endTime":"0","summary":"Leerink Partners Initiates BlossomHill Therapeutics at Outperform, $36 Price Target","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BLSM"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":44,"code":"91000000","status":"200"}]}}